Literature DB >> 1824

Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.

D P Van Kammen, D L Murphy.   

Abstract

Seven of nine depressed patients experienced a 4.3-fold increase in rated euphoria and activation following 30 mg d-amphetamine in a replicated dose, double blind study. d-Amphetamine was 2 to 2.3-fold more effective in producing activation, euphoria, and antidepressant effects than the same dose of l-amphetamine. Co-treatment with lithium carbonate produced a 60% (P less than 0.001) attenuation of the activation and euphoria responses to d-amphetamine. The responses to l-amphetamine were almost completely abolished by lithium. This study raises the possibility of lithium carbonate use as an adjunct in the treatment of amphetamine addiction.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1824     DOI: 10.1007/BF00428897

Source DB:  PubMed          Journal:  Psychopharmacologia


  31 in total

1.  THE EXCRETION OF DEXAMPHETAMINE AND ITS DERIVATIVES.

Authors:  A M ASATOOR; B R GALMAN; J R JOHNSON; M D MILNE
Journal:  Br J Pharmacol Chemother       Date:  1965-02

2.  Differential effects of D- and L-amphetamine on the sleep of depressed patients.

Authors:  J C Gillin; D P van Kammen; J Graves; D Murphy
Journal:  Life Sci       Date:  1975-10-15       Impact factor: 5.037

3.  Catecholamine metabolism, depressive illness, and drug response.

Authors:  J W Maas; J A Fawcett; H Dekirmenjian
Journal:  Arch Gen Psychiatry       Date:  1972-03

4.  The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C] amphetamine.

Authors:  A H Beckett; J A Salmon; M Mitchard
Journal:  J Pharm Pharmacol       Date:  1969-04       Impact factor: 3.765

Review 5.  Lithium in psychiatric therapy and prophylaxis.

Authors:  M Schou
Journal:  J Psychiatr Res       Date:  1968-06       Impact factor: 4.791

6.  DOPA and other naturally occurring substances as causes of stereotypy and rage in rats.

Authors:  A Randrup; I Munkvad
Journal:  Acta Psychiatr Scand Suppl       Date:  1966

7.  The effect of lithium and amphetamine on desmethylimipramine-Ro 4-1284 induced motor hyperactivity.

Authors:  N Matussek; M Linsmayer
Journal:  Life Sci       Date:  1968-04-01       Impact factor: 5.037

8.  Amphetamine abuse. Pattern and effects of high doses taken intravenously.

Authors:  J C Kramer; V S Fischman; D C Littlefield
Journal:  JAMA       Date:  1967-07-31       Impact factor: 56.272

9.  Rubidium and lithium: opposite effects on amine-mediated excitement.

Authors:  B J Carroll; P T Sharp
Journal:  Science       Date:  1971-06-25       Impact factor: 47.728

10.  Intravenous l-DOPA plus carbidopa in depressed patients: average evoked response, learning, and behavioral changes.

Authors:  G M Henry; M Buchsbaum; D L Murphy
Journal:  Psychosom Med       Date:  1976 Mar-Apr       Impact factor: 4.312

View more
  52 in total

1.  Dopaminergic system dysfunction in recreational dexamphetamine users.

Authors:  Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Acute nicotinic blockade produces cognitive impairment in normal humans.

Authors:  P A Newhouse; A Potter; J Corwin; R Lenox
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity.

Authors:  Alexandra S Potter; David J Bucci; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2011-10-04       Impact factor: 4.530

4.  Neurochemical and psychoanalytical approaches to mania.

Authors:  J C Cookson; T Silverstone
Journal:  Proc R Soc Med       Date:  1977

5.  Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans.

Authors:  David T Dao; Pamela Belmonte Mahon; Xiang Cai; Colleen E Kovacsics; Robert A Blackwell; Michal Arad; Jianxin Shi; Peter P Zandi; Patricio O'Donnell; James A Knowles; Myrna M Weissman; William Coryell; William A Scheftner; William B Lawson; Douglas F Levinson; Scott M Thompson; James B Potash; Todd D Gould
Journal:  Biol Psychiatry       Date:  2010-08-17       Impact factor: 13.382

6.  The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.

Authors:  Sargo Aalto; Jussi Hirvonen; Valtteri Kaasinen; Nora Hagelberg; Jaana Kajander; Kjell Någren; Timo Seppälä; Juha O Rinne; Harry Scheinin; Jarmo Hietala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

7.  TRH attenuates scopolamine-induced memory impairment in humans.

Authors:  S E Molchan; A M Mellow; B A Lawlor; H J Weingartner; R M Cohen; M R Cohen; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Alexandra S Potter; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

10.  Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder.

Authors:  Franklin R Schneier; Anissa Abi-Dargham; Diana Martinez; Mark Slifstein; Dah-Ren Hwang; Michael R Liebowitz; Marc Laruelle
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.